Oxford Biomedica PLC

Director's Dealing • Sep 19, 2013

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3661O

Oxford Biomedica PLC

19 September 2013

For immediate release	19 September 2013

Oxford BioMedica plc Director's Share Purchase

Oxford, UK - 19 September 2013: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, was informed on 18 September that one of its Directors has acquired ordinary shares of 1p each ("Ordinary Shares") as follows:

				Interest after purchase
Director / PDMR	Title	Price per share (p)	Number of Ordinary Shares acquired on 18 September 2013	Number of Ordinary Shares	% of total issued share capital
Andrew Heath	Non-Executive Director	2.58	100,000	600,000	0.042%

The issued share capital of the Company is 1,416,149,005 1p ordinary shares.

-Ends-

For further information, please contact:
Oxford BioMedica plc: Lara Mott, Head of Investor Relations and Corporate Communications	Tel: +44 (0)1865 783 000
Nomura Code Securities Limited: Juliet Thompson/Chris Golden	Tel: +44 (0)20 7776 1200
Media/Financial Enquiries: Mary-Jane Elliott/Emma Thompson/Matthew Neal Consilium Strategic Communications	Tel: +44 (0)20 7920 2354

Notes to editors

1. About Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.ukand www.oxbsolutions.co.uk.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSBRGDCXDBBGXI